Related Experiment Videos
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Gout Risk: A Population-Based Comparative
Hong Sang Choi1,2, Jaejun Heo3, Sungho Won3,4
1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
Aim:
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real-world data and Mendelian randomisation (MR) analysis.
Materials And Methods:
We conducted a population-based cohort study using the Korean National Health Insurance Service database (2015-2020). New users of SGLT2i were compared to dipeptidyl peptidase-4 inhibitor (DPP4i) users. After 1:1 propensity score matching (PSM), 20 866 pairs were analysed using Cox proportional hazards models. The primary outcome was incident gout. Additionally, a two-sample MR analysis utilised genetic variants in SLC5A2 as proxies for SGLT2 inhibition and gout summary statistics from the FinnGen consortium.
Results:
In the cohort study, SGLT2i use was associated with a significantly lower risk of gout compared to DPP4i (incidence rate: 2792.6 vs. 3346.7 per 100 000 person-years). The hazard ratio in the PSM model was 0.80 (95% confidence interval [CI] 0.76-0.84, p value < 0.001). This finding was robust across multiple sensitivity analyses, including landmark and time-varying exposure models. In the MR analysis, genetically proxied SGLT2 inhibition was associated with a reduced risk of gout (odds ratio 0.10 per 1-standard deviation decrease in HbA1c; 95% CI: 0.017-0.463; p value < 0.001), with consistent results across robust MR methods.
Conclusion:
SGLT2i therapy is associated with a lower risk of incident gout compared to DPP4i in patients with type 2 diabetes. While these findings suggest potential pleiotropic effects of SGLT2i beyond glucose control, they should be interpreted with caution given the limitations of observational study designs.
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Secondary Active Transport